Literature DB >> 1643699

High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.

C M Camaggi1, P Carisi, E Strocchi, F Pannuti.   

Abstract

A specific, sensitive, and reliable high-performance liquid chromatographic (HPLC) method for the determination of idarubicin (IDA) and its known fluorescent metabolites idarubicinol (IDAol) and 4-demethoxy-daunomycinone (AG1) in biological fluids (human plasma and urine) was developed and tested. Plasma samples were solid-phase-extracted (C18 bonded silica cartridges). Complete separation of unchanged drugs and metabolites was achieved on a Cyanopropyl chromatographic column (25 cm x 4.6 mm inside diameter; particle size, 5 microns) using fluorescence detection (excitation wavelength, 470 nm; emission wavelength, 580 nm). Sensitivity was better than 0.2 ng/ml for all analytes; rates of recovery of unchanged drug and metabolites were better than 84.5% (IDA), 80.3% (IDAol), and 83.9% (AG1). The interassay coefficient of variation was 6.5% for IDA, 5.8% for IDAol, and 9.8% for AG1. Mean intra-assay precision was 4.6% for IDA, 5.9% for IDAol, and 5.0% for AG1 at sample concentrations of above 1 ng/ml and 12.1% for IDA, 10.8% for IDAol, and 14.1% for AG1 at sample concentrations of below 1 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643699     DOI: 10.1007/bf00686300

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative.

Authors:  E Moro; V Bellotti; M G Jannuzzo; S Stegnjaich; G Valzelli
Journal:  J Chromatogr       Date:  1983-05-13

3.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

4.  Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.

Authors:  D B Smith; J M Margison; S B Lucas; P M Wilkinson; A Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.

Authors:  E Berman; R E Wittes; B Leyland-Jones; E S Casper; R J Gralla; J Howard; L Williams; R Baratz; C W Young
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

Review 6.  Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.

Authors:  F Ganzina; M A Pacciarini; N Di Pietro
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

7.  Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.

Authors:  A N Daghestani; Z A Arlin; B Leyland-Jones; T S Gee; S J Kempin; R Mertelsmann; D Budman; P Schulman; R Baratz; L Williams
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

8.  Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).

Authors:  K Lu; N Savaraj; J Kavanagh; L G Feun; M Burgess; G P Bodey; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.

Authors:  F Pannuti; C M Camaggi; E Strocchi; R Comparsi; B Angelelli; M A Pacciarini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  9 in total
  3 in total

1.  Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; A Tononi; M Guaraldi; M Strolin-Benedetti; C Efthymiopoulos; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.

Authors:  M M Buckley; H M Lamb
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

3.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.